Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn's disease

被引：0
|
作者：
Sieczkowska, J. [1 ]
Jarzebicka, D. [1 ]
Oracz, G. [1 ]
Meglicka, M. [1 ]
Dadalski, M. [1 ]
Kierkus, J. [1 ]
机构：
[1] Childrens Mem Hlth Inst, Dept Gastroenterol Hepatol Feeding Disorders & Pa, Warsaw, Poland
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P617
引用
收藏
页码：S413 / S414
页数：2
相关论文
共 50 条
  • [1] Unchanged infliximab serum concentrations after switching from the reference infliximab to the biosimilar CT-P13 in patients with quiescent Crohn's disease: a prospective study
    Strik, A.
    van de Vrie, W.
    van Megen, Y.
    Bloemsaat-Minekus, J.
    Rispens, T.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S420 - S420
  • [2] Immunogenicity of infliximab in Crohn's disease
    Hanauer, SB
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (21): : 2155 - 2156
  • [3] Induction Therapy With Biosimilar Infliximab in Children With Crohn Disease
    Sieczkowska-Golub, Joanna
    Meglicka, Monika
    Plocek, Yanna
    Banaszkiewicz, Aleksandra
    Jarzebicka, Dorota
    Toporowska-Kowalska, Ewa
    Gawronska, Agnieszka
    Oracz, Grzegorz
    Kierkus, Jaroslaw
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2017, 65 (03): : 285 - 288
  • [4] Effectiveness and safety of reference infliximab and biosimilar in Crohn's disease: a French equivalence study
    Meyer, A.
    Rudant, J.
    Drouin, J.
    Weill, A.
    Carbonnel, F.
    Coste, J.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S49 - S49
  • [5] Immunogenicity of infliximab in Crohn's disease - Reply
    Rutgeerts, P
    Baert, F
    Noman, M
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (21): : 2156 - 2156
  • [6] Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study
    Ribaldone, Davide Giuseppe
    Tribocco, Elisa
    Rosso, Chiara
    Armandi, Angelo
    Vernero, Marta
    Bugianesi, Elisabetta
    Astegiano, Marco
    Saracco, Giorgio Maria
    Caviglia, Gian Paolo
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (15)
  • [7] Infliximab switching from reference product to biosimilar: a review of evidence regarding the clinical efficacy, safety profile and immunogenicity
    Abidin, Ahmad Zainal
    Snoswell, Centaine L.
    Shafiee Hanjani, Leila
    Callaghan, Gavin
    Edmonds, Michelle
    JOURNAL OF PHARMACY PRACTICE AND RESEARCH, 2021, 51 (05) : 358 - 373
  • [8] UNCHANGED INFLIXIMAB SERUM CONCENTRATIONS AFTER SWITCHING FROM THE ORIGINATOR INFLIXIMAB TO THE BIOSIMILAR CT-P13 IN PATIENTS WITH QUIESCENT CROHN'S DISEASE: A PROSPECTIVE STUDY
    Strik, Anne S.
    van de Vrie, W.
    Megen, Yvonne
    Minekus, Joanne
    Rispens, Theo
    D'Haens, Geert R.
    GASTROENTEROLOGY, 2017, 152 (05) : S66 - S66
  • [9] Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study
    Meyer, Antoine
    Rudant, Jeremie
    Drouin, Jerome
    Weill, Alain
    Carbonnel, Franck
    Coste, Joel
    ANNALS OF INTERNAL MEDICINE, 2019, 170 (02) : 99 - +
  • [10] Switching from infliximab to biosimilar
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (07): : 475 - 475
12345